Search alternatives:
larger decrease » marked decrease (Expand Search)
linear decrease » linear increase (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
larger decrease » marked decrease (Expand Search)
linear decrease » linear increase (Expand Search)
teer decrease » mean decrease (Expand Search), greater decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
1761
-
1762
-
1763
-
1764
-
1765
-
1766
-
1767
-
1768
-
1769
-
1770
-
1771
-
1772
-
1773
<b> </b> Rate of brain weight to body weight in different experimental groups. AlCl3 treatment caused a significant decrease in brain-to-body weight with respect to the control group (P < 0.01). 2 or 5 injections of BM-MSC extracted exosomes significantly protected against the deficit effect of Alcl3 on brain-to-body weight rate....
Published 2025“…AlCl3 treatment caused a significant decrease in brain-to-body weight with respect to the control group (P < 0.01). 2 or 5 injections of BM-MSC extracted exosomes significantly protected against the deficit effect of Alcl3 on brain-to-body weight rate. …”
-
1774
-
1775
Demographic information of participants.
Published 2025“…The longitudinal results showed a decreasing trend of negative correlation between AB and PA under T1-T3 stages (r = −0.29, r = −0.44, P < 0.01), and no significant change in the degree of negative correlation with HSK (r = −0.28, r = −0.35, P < 0.01). …”
-
1776
Evogliptin attenuates the pyroptotic cell death of VSMCs during CER treatment by decreasing the pyroptotic-associated genes and GSDM-D cleavage efficiency <i>in-vitro.</i>
Published 2025“…<p>(A) Bar graph showed EVO significantly decreased Lactate dehydrogenase (LDH) release in CER treated P<sub>i</sub>‐induced VSMCs. …”
-
1777
-
1778
-
1779
-
1780
Flowchart of the screening process.
Published 2025“…Efficacy was assessed through intraoperative outcomes, primary postoperative outcomes, and statistically significant postoperative outcomes. Patients with thyroid disorders undergoing TOTVA experienced longer overall operative time and hospital stays, reduced intraoperative blood loss, increased lymph node retrieval, higher incidence of infection, lower postoperative pain scores, reduced incidence of hypocalcemia, larger drainage volumes, and higher cosmetic effect scores compared with those undergoing.…”